Diabetic injections for weight loss: who they're for and how they work

You've seen these medicines mentioned in a diabetes context, here's why that's only half the story

The confusion is understandable. Tirzepatide and semaglutide both started life as treatments for type 2 diabetes, and that history is hard to separate from how they're discussed online. A lot of people arrive here assuming they'd need a diabetes diagnosis to access them. They don't. If you're looking into non-diabetic weight loss injections, it helps to know that Mounjaro (tirzepatide) and Wegovy (semaglutide injection) each hold their own UK licences for weight loss in adults who meet the relevant BMI threshold, regardless of whether they have diabetes.

The mechanism that makes them effective for blood-sugar control is closely related to why they reduce appetite. Both medicines act on receptors involved in gut-hormone signalling, GLP-1 receptors in the case of semaglutide, and both GIP and GLP-1 receptors in the case of tirzepatide. That dual action is what makes tirzepatide the only medicine of its kind currently licensed in the UK. The practical result, for most people, is a meaningful reduction in hunger and a slower gastric-emptying rate, both of which make eating less feel considerably more manageable. The NHS patient information page for tirzepatide covers the mechanism in plain language if you'd like the detail.

Ozempic, it's worth knowing, is also semaglutide, but it carries a diabetes licence only, not a weight-management one. If you're curious about how a diabetic injection comes to be used for weight loss, that distinction matters more than it might seem, because a prescriber's clinical and legal duty of care is shaped by it.

What the trial evidence actually showed, and what it didn't guarantee

Two large randomised trials are the bedrock here. STEP 1 followed 1,961 adults with obesity but without diabetes over 68 weeks; participants taking semaglutide 2.4 mg alongside lifestyle support lost an average of around 15% of body weight, compared with around 2.4% on placebo. The SURMOUNT-1 trial, which enrolled 2,539 adults and ran for 72 weeks, found average weight reductions of around 20–21% at tirzepatide's highest dose. Both were published in the New England Journal of Medicine and form part of the evidence base reviewed by NICE.

NICE subsequently recommended tirzepatide for NHS use in adults with a BMI of 35 or above plus at least one weight-related health condition, under technology appraisal TA1026. Semaglutide was recommended earlier under TA875, though with a requirement for use within specialist weight management services and for a maximum of two years.

None of that means results are guaranteed for any individual. Trial averages mask real variation, some participants lost considerably more, others considerably less. What the evidence does show clearly is that, in a large and well-designed study population, the effect was substantial and statistically significant. Your own response depends on factors a prescriber assesses at consultation, not on a trial headline. Understanding who tends to respond well is a useful place to start thinking about that.

Who these medicines are suitable for (and where caution is needed

Private eligibility, per the medicine licences, covers adults with a BMI of 30 or above, or 27 or above if at least one weight-related condition is present) examples include high blood pressure, raised cholesterol, obstructive sleep apnoea, prediabetes or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI is one input into the decision, not the whole of it.

There are situations where these medicines are not suitable, and a responsible clinical service is clear about them. Neither tirzepatide nor semaglutide is recommended during pregnancy, while breastfeeding, or if you're actively trying to conceive. Neither is licensed for under-18s. A personal or family history of medullary thyroid carcinoma or MEN2, or a history of pancreatitis, requires specific clinical discussion, these are not automatic exclusions in every case, but they're not something to skip past either.

One practical note on contraception: if you take the oral contraceptive pill and start tirzepatide, NHS guidance recommends adding a non-oral method such as condoms for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be reduced. Semaglutide does not carry the same advisory. If you're using hormonal contraception, mention it at your consultation, a prescriber will advise. The NHS England guidance on weight-management injections covers this and other practical considerations in detail.

If you're on other medicines or managing existing health conditions, a thorough medication review at the point of assessment is exactly what the consultation is for. Our clinical team at nume reviews every consultation personally, a prescriber reads your answers, not a script.

Getting access through a regulated UK pharmacy

In the UK, both tirzepatide and semaglutide for weight management are available only on prescription. There is no legal route that bypasses clinical assessment. The MHRA has made this explicit in public guidance, and enforcement against illegal sellers (including the seizure of around 20 million doses of counterfeit weight-loss medicines worth roughly £45 million) has increased significantly since 2023. Buying from an unverified online seller carries a genuine safety risk; fake pens have been found to contain insulin rather than the labelled medicine.

The straightforward check: any legitimate UK online pharmacy can be verified on the GPhC register. nume's GPhC pharmacy registration number is 9012878. Treatment sourced through a GPhC-registered pharmacy using the licensed UK supply chain is the safe route, the only one worth considering for a prescription medicine. If you'd like to explore your options, this page on where to buy weight-loss injections legally in the UK sets out the full picture.

To find out whether you're clinically suitable, the starting point is a free consultation. Speak to our prescribers, no referral, no waiting list, same-day clinical review once you've submitted your answers.